February 24, 2022
Chimerix, READDI at UNC Announce Preclinical Data on COVID Anti-viral Treatment
The compound CMX521 significantly reduced lung viral titer and symptoms in a SARS-CoV-2 mouse model, as reported by biomedical company Chimerix in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at UNC-Chapel Hill. UNC School of Medicine faculty Nat Moorman, PhD, and Mark Heise, PhD, are key researchers in this program.